down arrow

Actinium Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00507W2061
USD
1.45
0.00 (0.00%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.421.49

52 Week

1.032.41
Valuation
Technical
Day's Volume

CASH

6.98 k

Shareholding (Mar 2025)

FII

3.36%

Held by 25 FIIs

DII

82.46%

Held by 15 DIIs

Promoter

0.00%

How big is Actinium Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Actinium Pharmaceuticals, Inc. has a market capitalization of 44.61 million, with net sales of 0.00 million and a net profit of -45.51 million over the latest four quarters. Shareholder's funds are 32.76 million, and total assets are 76.90 million.

Market Cap: As of Jun 18, Actinium Pharmaceuticals, Inc. has a market capitalization of 44.61 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -45.51 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 32.76 million, while total assets were reported at 76.90 million.

Read More

What does Actinium Pharmaceuticals, Inc. do?

22-Jun-2025

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. As of March 2025, it has a market cap of $44.61 million and reported a net loss of $16 million.

Overview:<BR>Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in developing cancer treatments within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 44.61 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -2.52<BR>- Return on Equity: -177.13%<BR>- Price to Book: 1.74<BR><BR>Contact Details:<BR>- Address: 275 Madison Ave Fl 7, NEW YORK NY: 10016-1101<BR>- Tel: 1 646 6773875<BR>- Website: https://www.actiniumpharma.com/

Read More

Who are in the management team of Actinium Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Actinium Pharmaceuticals, Inc. includes Mr. Sandesh Seth (Chairman and CEO), Dr. C. David Nicholson (Lead Independent Director), and Independent Directors Dr. Jeffrey Chell, Dr. Ajit Shetty, and Mr. Richard Steinhart. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Actinium Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Sandesh Seth, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Dr. C. David Nicholson, who is the Lead Independent Director.<BR>- Dr. Jeffrey Chell, an Independent Director.<BR>- Dr. Ajit Shetty, also an Independent Director.<BR>- Mr. Richard Steinhart, another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Actinium Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2023, Actinium Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its low valuation score of -0.9802, a Price to Book Value of 2.22, and a poor one-year return of -79.21%, making it a potentially unviable investment compared to its peers.

As of 15 May 2023, the valuation grade for Actinium Pharmaceuticals, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, particularly given its P/E ratio is not applicable due to losses, while its Price to Book Value stands at 2.22. Additionally, the EV to EBIT and EV to EBITDA ratios are both at a low 0.16, suggesting that the market is not valuing the company's earnings potential favorably.<BR><BR>In comparison to its peers, Actinium Pharmaceuticals has a valuation score of -0.9802, while Fusion Pharmaceuticals, Inc. has a P/E of -17.5788 and Zevra Therapeutics, Inc. has a P/E of -5.0550, both indicating a challenging environment for similar firms. The company's return over the past year has been particularly poor at -79.21%, contrasting sharply with the S&P 500's return of 10.26%, further reinforcing the notion that Actinium may not be a viable investment at its current valuation.

Read More

Is Actinium Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Actinium Pharmaceuticals, Inc. shows a mildly bullish trend, supported by the MACD and daily moving averages, despite mixed signals from Bollinger Bands and underperformance against the S&P 500 in the short term.

As of 12 August 2025, the technical trend for Actinium Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The MACD is showing a mildly bullish stance on both the weekly and monthly time frames, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. The daily moving averages are also mildly bullish. However, the Bollinger Bands present a mixed picture with a bullish signal on the weekly and a bearish signal on the monthly. The KST is mildly bearish on the weekly and bearish on the monthly, and Dow Theory shows no trend on both time frames.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.79% and -3.51% compared to 1.05% and 2.33% for the index, respectively. However, it has outperformed the S&P 500 year-to-date with a return of 30.95% versus 12.22%. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and daily moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 50 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-3.12

stock-summary
Return on Equity

-215.83%

stock-summary
Price to Book

2.63

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.2%
0%
-14.2%
6 Months
-15.2%
0%
-15.2%
1 Year
19.83%
0%
19.83%
2 Years
-73.92%
0%
-73.92%
3 Years
-87.13%
0%
-87.13%
4 Years
-77.17%
0%
-77.17%
5 Years
-86.62%
0%
-86.62%

Actinium Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Actinium Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Actinium Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The MACD is showing a mildly bullish stance on both the weekly and monthly time frames, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. The daily moving averages are also mildly bullish. However, the Bollinger Bands present a mixed picture with a bullish signal on the weekly and a bearish signal on the monthly. The KST is mildly bearish on the weekly and bearish on the monthly, and Dow Theory shows no trend on both time frames. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.79% and -3.51% compared to 1.05% and 2.33% for the index, respectively. However, it has outperformed the S&P 500 year-to-date with a return of 30.95% versus 12.22%. Overall, the current technical stance is mildly ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-153.97%
EBIT to Interest (avg)
-37.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.52
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.93%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.22
EV to EBIT
0.16
EV to EBITDA
0.16
EV to Capital Employed
0.20
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
125.92%
ROE (Latest)
-177.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (14.19%)

Foreign Institutions

Held by 25 Foreign Institutions (3.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 56.60% vs -137.31% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.30",
          "val2": "-16.40",
          "chgp": "55.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.90",
          "val2": "-15.90",
          "chgp": "56.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -88.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.72% vs -47.88% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.30",
          "val2": "-51.10",
          "chgp": "19.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.20",
          "val2": "-48.80",
          "chgp": "21.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-640,987.70%",
          "chgp": "64,098.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.30
-16.40
55.49%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.90
-15.90
56.60%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 56.60% vs -137.31% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-41.30
-51.10
19.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-38.20
-48.80
21.72%
Operating Profit Margin (Excl OI)
0.00%
-640,987.70%
64,098.77%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -88.89% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 21.72% vs -47.88% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Actinium Pharmaceuticals, Inc. stock-summary
stock-summary
Actinium Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
Company Coordinates stock-summary
Company Details
275 Madison Ave Fl 7 , NEW YORK NY : 10016-1101
stock-summary
Tel: 1 646 6773875
stock-summary
https://www.actiniumpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."